These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18226005

  • 21. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm.
    Perazella MA.
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):519-25. PubMed ID: 19623065
    [Abstract] [Full Text] [Related]

  • 22. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [Abstract] [Full Text] [Related]

  • 23. Tissue deposition of gadolinium and development of NSF: a convergence of factors.
    Perazella MA.
    Semin Dial; 2008 May; 21(2):150-4. PubMed ID: 18226004
    [Abstract] [Full Text] [Related]

  • 24. Nephrogenic systemic fibrosis.
    Nainani N, Panesar M.
    Am J Nephrol; 2009 May; 29(1):1-9. PubMed ID: 18663283
    [Abstract] [Full Text] [Related]

  • 25. [Nephrogenic systemic fibrosis].
    Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A.
    G Ital Nefrol; 2008 May; 25(1):14-20. PubMed ID: 18264914
    [Abstract] [Full Text] [Related]

  • 26. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G, Abu-Alfa A.
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [Abstract] [Full Text] [Related]

  • 27. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
    Penfield JG, Reilly RF.
    Semin Dial; 2008 May; 21(2):129-34. PubMed ID: 18225999
    [Abstract] [Full Text] [Related]

  • 28. [Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn?].
    Ortega LM, Contreras G, Lenz O.
    Nefrologia; 2009 May; 29(2):109-17. PubMed ID: 19396315
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR.
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
    Perazella MA.
    Curr Drug Saf; 2008 Jan; 3(1):67-75. PubMed ID: 18690983
    [Abstract] [Full Text] [Related]

  • 33. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
    Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P.
    Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR, Chopard CS, Martin PY, Vallée JP.
    Rev Med Suisse; 2008 Mar 05; 4(147):576-8, 580. PubMed ID: 18402015
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.